Citigroup Inc. Sells 226,396 Shares of Sanofi $SNY

Citigroup Inc. reduced its holdings in shares of Sanofi (NASDAQ:SNY) by 48.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,253 shares of the company’s stock after selling 226,396 shares during the quarter. Citigroup Inc.’s holdings in Sanofi were worth $11,434,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Mondrian Investment Partners LTD bought a new stake in Sanofi during the 3rd quarter valued at $171,742,000. Raymond James Financial Inc. grew its position in shares of Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after purchasing an additional 2,635,867 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Sanofi by 10,152.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock valued at $103,846,000 after purchasing an additional 2,178,647 shares during the period. Regal Partners Ltd lifted its holdings in Sanofi by 102.3% during the 2nd quarter. Regal Partners Ltd now owns 1,548,204 shares of the company’s stock worth $74,794,000 after purchasing an additional 782,838 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its stake in Sanofi by 1,853.1% in the 2nd quarter. NewEdge Advisors LLC now owns 731,208 shares of the company’s stock worth $35,325,000 after purchasing an additional 693,770 shares during the period. 14.03% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Barclays cut Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Citigroup initiated coverage on shares of Sanofi in a research note on Tuesday, January 27th. They issued a “neutral” rating on the stock. UBS Group reissued a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. TD Cowen reaffirmed a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Finally, HSBC reiterated a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Five analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, Sanofi presently has an average rating of “Hold” and an average price target of $62.67.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $48.66 on Friday. The company’s fifty day moving average price is $47.54 and its 200-day moving average price is $48.58. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. The firm has a market capitalization of $118.68 billion, a price-to-earnings ratio of 13.52, a PEG ratio of 1.26 and a beta of 0.45. Sanofi has a one year low of $44.62 and a one year high of $60.12.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.